Summary
Background. In Gaucher disease, the infiltration of the bone marrow by glucocerebroside-laden macrophages (Gaucher cells) triggers a diverse pattern of skeletal disease that results in crippling complications. Reliable ascertainment of the severity and pattern of skeletal disease is essential to determine disease status and the response to enzyme replacement therapy (ERT). Although there is ample documentation of reversal of haematological and visceral disease by ERT, there is a paucity of data on skeletal response to ERT in children.
Aim. To delineate the pattern of bone disease in children with Gaucher disease in Egypt and to evaluate its response to ERT.
Method. Twenty-two children with Gaucher disease were treated with ERT. Phenotyping by clinical, laboratory and radiological criteria was performed at baseline and following 11.2 ± 4 months of ERT. Genotyping for glucocerebrosidase (GBA) mutations was performed by gene sequencing, and genotype–phenotype correlations were performed.
Results. Two-thirds of the patients were from consanguineous pedigrees and 14/22 patients were homozygous or compound heterozygous for L444P and D409H mutations. Bone involvement was detected by plain radiology in 11 children (50%) and in 16 (73%) by magnetic resonance imaging (MRI). There was no correlation of severity of bone involvement and GBA genotype. ERT ameliorated bone disease: 10 of the 11 children with abnormal radiographic findings at baseline showed improvement in skeletal lesions; while 9/16 showed improvement of marrow disease by MRI. Radiographic sensitivity and specificity were 62% and 82% compared to MRI for detection of bone involvement in this patient population. At baseline, bone pain was present in 5 patients and ERT resulted in complete symptomatic remission in all of them. ERT was associated with significant improvement in growth parameters and amelioration of haematological and visceral involvement.
Conclusion. Symptomatic and radiological skeletal disease is common in children with Gaucher disease in Egypt. MRI is the most accurate technique for detecting early skeletal involvement. There was no correlation between severity of skeletal involvement and GBA genotype. ERT was effective in ameliorating radiological manifestations of skeletal disease and achieving complete remission of bone pain.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- +ve PV::
-
positive predictive value
- −ve PV::
-
negative predictive value
- +ve LR::
-
positive likelihood ratio
- −ve LR::
-
negative likelihood ratio
References
Armitage P, Berry G (1994) Statistical Methods in Medical Research, 3rd edn. Oxford: Blackwell Scientific Publications.
Bembi B, Ciana G, Mengel E, Terk MR, Martini C, Wenstrup RJ (2002) Bone complications in children with Gaucher disease. Br J Radiol 75(Supplement 1): A37–A43.
Beutler E, Grabowski GA (2001) Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3635–3668.
Elstein D, Hadas-halpern I, Itzchaki M, Lahad A, Abrahamov A, Zimran A (1996) Effect of low dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells Mol Dis 22: 104–111.
Giraldo P, Pocovi M, Perez-Calvo J, Rubio-Felix D, Giralt M (2000) Report of the Spanish Gaucher’s disease registry: clinical and genetic characteristics. Haematologica 85(8): 792–799.
Hsu CC, Chien YH, Lai MY, Hwu WL (2002) Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease. J Formos Med Assoc 101(9): 627–631.
Kauli R, Zaizov R, Lazar L, et al (2000) Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy. Isr Med Assoc J 2(2): 158–163.
Korolenko TA, Zhanaeva SY, Falameeva OK, et al (2000) Chitotriosidase as a marker of macrophage stimulation. Bull Exp Biol Med 130: 948–950.
Maas M, Poll LW, Terk MR (2002) Imaging and quantifying skeletal involvement in Gaucher disease. Br J Radiol 75(Supplement 1): A13–A24.
Pastores GM, Patel MJ, Firooznia H (2000) Bone and joint complications related to Gaucher disease. Curr Rheumatol Rep 2: 175–180.
Pastores GM, Weinreb NJ, Aerts H, et al (2004) Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41(4 Supplement 5): 4–14.
Poll LW, Koch JA, Willers R, et al (2002a) Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease. Blood Cells Mol Dis 28(2): 209–220.
Poll LW, Maas M, Terk MR, et al (2002b) Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 75(Supplement 1): A25–A36.
Schaison G, Caubel I, Belmatoug N, Billette de Villemeur T, Saudubray JM (2002) French results of enzyme replacement therapy in Gaucher’s disease. Bull Acad Natl Med 186(5): 851–861.
Schiffmann R, Mankin H, Dambrosia JM, et al (2002) Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 28(2): 288–296.
Sidransky E (2004) Gaucher disease: complexity in a “simple” disorder. Mol Genet Metab 83(1–2): 6–15.
Tayebi N, Stern H, Dymarskaia I, Herman J, Sidransky E (1996) 55-Base pair deletion in certain patients with Gaucher disease complicates screening for common Gaucher alleles. Am J Med Genet 66(3): 316–319.
Terk MR, Dardashti S, Liebman HA (2000) Bone marrow response in treated patients with Gaucher disease. Evaluation by T1-weighted magnetic response images and correlation with reduction in liver and spleen volume. Skeletal Radiol 29: 563–571.
Weinreb NJ (2004) Introduction. Advances in Gaucher Disease: Therapeutic goals and evaluation and monitoring guidelines. Semin Hematol. 41(4 Supplement 5): 1–3.
Weinreb NJ, Charrow J, Andersson HC, et al (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113(2): 112–119.
Wenger DA, Clark C, Sattler M, Wharton C (1978) Synthetic substrate β-glucoside activity in leucocytes; a reproducible method for the identification of the patients and carriers of Gaucher disease. Clin Genet 13: 145–153.
Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B (2002) Skeletal aspects of Gaucher disease: A review. Br J Radiol 75(Supplement 1): A2–A12.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicating editor: Guy Besley
Competing interests: None declared
Rights and permissions
About this article
Cite this article
El-Beshlawy, A., Ragab, L., Youssry, I. et al. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. J Inherit Metab Dis 29, 92–98 (2006). https://doi.org/10.1007/s10545-006-0121-6
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10545-006-0121-6